We previously demonstrated that treatment of CMT rats with the recombinant growth factor neuregulin-1 early postnatally (P6–P18) significantly improves CMT1A disease pathology8. The gene discussed is NRG1; the disease is Charcot-Marie-Tooth disease type 1A.